Traitement des syndromes myélodysplasiques de bas risque
Bulletin du Cancer · 2023
DOI: 10.1016/j.bulcan.2023.02.027 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bulletin du Cancer, 2023. Verfasst von Sophie Park. Beteiligte Einrichtung: CHU de Grenoble, service d'hématologie, CS 10217, 38043 Grenoble cedex 09, France. Electronic address: spark@chu-grenoble.fr. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Anemia, Hematinics, Thrombocytopenia. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
For low-risk myelodysplastic syndromes, the goal of treatment is to correct cytopenias or their consequences. Erythropoiesis-stimulating agents have an important role in the management of anemia. In this chapter, we will detail the response to ESAs, the factors predictive of response to ESAs. However, the search for new therapeutic options for low-risk, ESA-resistant MDS remains necessary as the incidence of AML transformation of the patients is higher. We can retain luspatercept for MDS with excess ring of sideroblasts, lenalidomide, and some molecules currently being tested such as imetelstat or roxedustat. However, the search for new therapeutic options for ESA-resistant low-risk MDS remains necessary. We can use androgenotherapy or TPO agonists in limited access for symptomatic thrombocytopenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CHU de Grenoble, service d'hématologie, CS 10217, 38043 Grenoble cedex 09, France. Electronic address: spark@chu-grenoble.fr.
Zitieren
APA
Park, S. (2023). Traitement des syndromes myélodysplasiques de bas risque. Bulletin du Cancer. https://doi.org/10.1016/j.bulcan.2023.02.027
Vancouver
Park S. Traitement des syndromes myélodysplasiques de bas risque. Bulletin du Cancer. 2023. doi:10.1016/j.bulcan.2023.02.027
BibTeX
@article{Park2023,
author = {Park, Sophie},
title = {Traitement des syndromes myélodysplasiques de bas risque},
journal = {Bulletin du Cancer},
year = {2023},
doi = {10.1016/j.bulcan.2023.02.027}
}
EUVIMED